Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €43.05 EUR
Change Today -0.295 / -0.68%
Volume 0.0
GS7A On Other Exchanges
Symbol
Exchange
OTC US
Xetra
Mexico
Frankfurt
As of 4:22 AM 04/2/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GS7A) Snapshot

Open
€42.60
Previous Close
€43.35
Day High
€43.10
Day Low
€42.01
52 Week High
03/19/15 - €45.48
52 Week Low
10/16/14 - €32.40
Market Cap
104.7B
Average Volume 10 Days
147.0
EPS TTM
--
Shares Outstanding
2.4B
EX-Date
02/18/15
P/E TM
--
Dividend
€2.65
Dividend Yield
4.77%
Current Stock Chart for GLAXOSMITHKLINE PLC-SPON ADR (GS7A)

glaxosmithkline plc-spon adr (GS7A) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

97,921 Employees
Last Reported Date: 02/26/15
Founded in 1935

glaxosmithkline plc-spon adr (GS7A) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.0M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.2M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $2.3M
Compensation as of Fiscal Year 2014.

glaxosmithkline plc-spon adr (GS7A) Key Developments

GlaxoSmithKline Signs Agreement with UK Department of Health

GlaxoSmithKline has signed a contract with UK Department of Health. The contract has been signed to launch a new vaccine to prevent meningitis caused by meningococcal group B bacteria for all babies in the country. The meningitis B vaccine will be launched as part of the National Health Service's immunization programme, which is scheduled to be initiated in September. GlaxoSmithKline acquired the vaccine called Bexsero from Novartis, which resulted in the price of the vaccine being decreased. The vaccine will now be added to the national childhood immunization programme, while babies will receive the first vaccine at two months old, followed by two further doses.

Department Of Health Reaches Agreement with GlaxoSmithKline plc on Meningitis Vaccine Bexsero

GlaxoSmithKline has reached an agreement with the United Kingdom's Department of Health (DoH) over the pricing of the firm's meningitis B vaccine Bexsero (meningococcal group-B vaccine [rDNA, component, adsorbed]). The vaccine will be added to the national childhood immunisation scheme, and babies will be immunised first at the age of two months, followed by two more doses.

GlaxoSmithKline Enters into Agreement with the UK Department of Health

GlaxoSmithKline (GSK) has entered into an agreement with the UK Department of Health to introduce a new vaccine to prevent meningitis caused by meningococcal group B bacteria for all babies in the country. The meningitis B vaccine will be introduced as part of the National Health Service's (NHS) NHS immunization program, which is scheduled to be initiated in September 2015. The vaccine will now be added to the national childhood immunization program, while babies will receive the first vaccine at two months old, followed by two further doses. The agreement offers fair value for the NHS and allows a reasonable return for the company to ensure that it can continue to invest in creating new treatments and vaccines.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GS7A:GR €43.05 EUR -0.295

GS7A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $162.52 USD -2.43
AbbVie Inc $57.10 USD -1.44
Actavis plc $296.43 USD -1.19
Amgen Inc $157.10 USD -2.75
Novo Nordisk A/S kr377.00 DKK +5.00
View Industry Companies
 

Industry Analysis

GS7A

Industry Average

Valuation GS7A Industry Range
Price/Earnings 26.0x
Price/Sales 3.1x
Price/Book 16.6x
Price/Cash Flow 26.0x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.